|Day Low/High||164.24 / 165.98|
|52 Wk Low/High||133.65 / 179.92|
I could be wrong, but as far as I can tell, nobody else is telling the story about the sudden movement in these yields.
The fiscal football remains a greater threat this week than anything Fed Chair Jerome Powell says on Zoom this Friday.
Investors come into this week with 'all eyes' on the Kansas City Fed's economic symposium come week's end.
AbbVie has been a Sarge fave for a long time. Sarge has been rewarded for trusting this firm's management when they acquired Allergan as a means toward replacing expected reductions in cash flows moving forward as the firm's patents for winder dru...
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...
These guys are aware that the U.S. was energy independent less than a year and a half ago, right?
One thing we know is that the current wave of the pandemic just seems to be getting worse.
Imagine if the SEC did not prohibit underwriters from lending out shares to short-sellers for 30 days after an IPO?
The Delta virus has more power to control both fiscal and monetary policy than does the data or do any of our leaders individually.
Also, there's reason to turn J&J's one shot jab into a two shot vaccine just like the rest.
Break in! sold off just now on this tweet: *FDA EXPECTED TO ANNOUNCE NEW WARNING ON J&J COVID VACCINE: WAPO This should help with the vaccine uptake — zerohedge (@zerohedge) July 12, 2021
And I was right, and the cynics were wrong. Here's why that matters more than ever now.
Here's where traders could probe the long side of JNJ.
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
Probably the best news right now is that individual stock picking has improved.
High-quality drugmaker AbbVie has several promising products aside from Humira and the market has priced the stock at a bargain.
Debt-free and poised to gain from its COVID-19 vaccine demand, MRNA could inject some life into your investment plan.
These Dividend Aristocrats have free DRIPs, long histories of raising their dividends, and attractive yields well above the market average.
The market seems to rejoice from the latest mask utterance out of the CDC, but the action at the Nasdaq should give traders pause.
ARCT's IP is incredibly valuable, and may in fact be invaluable.
UPS and FDX are both in serious rally mode, yet in very different places in terms of technical development.
When you hear about chip shortage you need to think of Lam. The world needs Lam to add to capacity as fast as possible.